Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $655,290.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the completion of the sale, the insider owned 137,643 shares of the company’s stock, valued at approximately $30,065,360.49. This represents a 2.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The stock was sold at an average price of $202.84, for a total value of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The stock was sold at an average price of $203.69, for a total value of $693,564.45.
• On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total value of $445,346.20.
• On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total value of $606,900.00.
• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.

Natera Trading Down 3.1%

NASDAQ:NTRA opened at $215.31 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The company has a market cap of $30.83 billion, a price-to-earnings ratio of -132.09 and a beta of 1.56. The stock has a fifty day simple moving average of $204.19 and a 200-day simple moving average of $216.06.

Institutional Investors Weigh In On Natera

A number of large investors have recently modified their holdings of the business. Horizon Investments LLC lifted its holdings in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC lifted its holdings in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. lifted its holdings in Natera by 3.1% in the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 46 shares during the period. Parallel Advisors LLC lifted its holdings in Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after acquiring an additional 47 shares during the period. Finally, First Horizon Corp lifted its holdings in Natera by 5.5% in the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on NTRA shares. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler reiterated an “overweight” rating and set a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. William Blair started coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Finally, The Goldman Sachs Group started coverage on Natera in a research note on Friday. They set a “neutral” rating and a $245.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $256.12.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.